# National Health and Medical Research Council

Entity Resources and Planned Performance

# National Health and Medical Research Council

[Section 1: Entity Overview and Resources 352](#_Toc71465239)

[1.1 Strategic Direction Statement 352](#_Toc71465240)

[1.2 Entity Resource Statement 353](#_Toc71465241)

[1.3 Budget Measures 354](#_Toc71465242)

[Section 2: Outcomes and Planned Performance 355](#_Toc71465243)

[2.1 Budgeted Expenses and Performance 355](#_Toc71465244)

[Section 3: Budgeted Financial Statements 360](#_Toc71465245)

[3.1 Budgeted Financial Statements 360](#_Toc71465246)

[3.2 Budgeted Financial Statements Tables 361](#_Toc71465247)

## Section 1: Entity Overview and Resources

### 1.1 Strategic Direction Statement[[1]](#footnote-1)

The National Health and Medical Research Council (NHMRC) is the Australian Government’s key entity for managing investment in health and medical research. NHMRC is also responsible for developing evidence-based health advice for the Australian community, health professionals and governments, and for promoting the highest standards of ethics and integrity in health and medical research.

NHMRC continues to support high quality research through its grant program, which encourages innovation in research and provides opportunities for talented researchers at all career stages. This work is facilitated by NHMRC’s modern grants management solution, Sapphire, which is helping to streamline grant application, peer review assessment and grant management processes.

NHMRC’s work also facilitates and promotes the translation of evidence from health and medical research into practices and policies designed to prevent illness and improve public health. NHMRC’s guidelines and advice support states and territories in achieving consistent standards in public and environmental health. NHMRC continues to consider strategic alignment with, and support the delivery of, Medical Research Future Fund grant opportunities.

The role and functions of NHMRC are set out in the *National Health and Medical Research Council Act 1992*. NHMRC also has statutory obligations under the *Prohibition of Human Cloning for Reproduction Act 2002,* the *Research Involving Human Embryos Act 2002*, and the *Medical Research Future Fund Act 2015*. NHMRC is a non‑corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

### 1.2 Entity Resource Statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‛Budgeted expenses by outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: NHMRC Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23Estimate**$'000 |
| **DEPARTMENTAL** |  |   |
| Prior year appropriation available | 7,298 | 4,798 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation | 36,877 | 37,200 |
| s74 retained revenue receipts (b) | 15,451 | 16,749 |
| Departmental Capital Budget (c) | 177 | 179 |
| Other services (d) |  |   |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **52,505** | **54,128** |
| **Total departmental resourcing for NHMRC** | **59,803** | **58,926** |

Table 1.1: NHMRC Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022 (continued)

|  |  |  |
| --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23Estimate**$'000 |
| **ADMINISTERED** |  |   |
| **Annual appropriations** |  |   |
| Ordinary annual services (a) |  |   |
| Outcome 1 | 878,460 | 893,049 |
| Other services (d) |  |   |
| Administered assets and liabilities | - | - |
| **Total administered annual appropriations** | **878,460** | **893,049** |
| **Special accounts (e)** |  |  |
| Opening balance | 216,939 | 215,698 |
| Appropriation receipts | 863,266 | 877,952 |
| Appropriation receipts - other entities (f) | - | - |
| Non-appropriation receipts  | 5,000 | 10,000 |
| **Total special accounts** | **1,085,205** | **1,103,650** |
| **Total administered resourcing**  | **1,963,665** | **1,996,699** |
| Less appropriations drawn from annual or special appropriations above and credited to special accounts (g) | (863,266) | (877,952) |
| **Total administered resourcing** | **1,100,399** | **1,118,747** |
| **Total resourcing for NHMRC** | **1,160,202** | **1,177,673** |
|  |  |  |
|  | **2021–22** | **2022–23** |
| **Average staffing level (number)** | 183 | 178 |

All figures are GST exclusive.

(a) *Appropriation Act (No. 1) 2022–23.*

(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(d) *Appropriation Act (No. 2) 2022–23.*

(e) For further information on special appropriations and special accounts, please refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1 within this chapter for further information on Outcome and Program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

(f) Appropriation receipts from the Department of Health.

(g) Appropriation receipts included above.

### 1.3 Budget Measures

This section is not applicable to NHMRC.

## Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to government outcomes over the Budget and forward years.

Each outcome is described within this section, together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

**Note:**

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth Performance Framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measures described in Portfolio Budget Statements will be read with broader information provided in an entity’s Corporate Plan and Annual Performance Statement – included in Annual Reports – to provide an entity’s complete performance story.

NHMRC’s most recent Corporate Plan and Annual Performance Statement are available at: www.nhmrc.gov.au/about-us/publications

### 2.1 Budgeted Expenses and Performance

**Outcome 1**

Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health

#### Program Contributing to Outcome 1

**Program 1.1: Health and Medical Research**

#### Linked Programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health (Health)Program 1.1: Health Research, Coordination and AccessProgram 1.8: Health Protection, Emergency Response and RegulationHealth contributes to health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future, and drive further medical innovation. |

#### Budgeted Expenses for NHMRC

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses and Resources for NHMRC

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **Program 1.1: Health and Medical Research** |
| Administered expenses |  |   |  |  |  |
| Ordinary annual services (a) | 878,460 | 893,049 | 903,951 | 918,415 | 932,192 |
| to Medical Research Endowment Account | (863,266) | (877,952) | (891,094) | (905,355) | (918,985) |
| Special accounts |  |   |  |  |  |
| Medical Research Endowment Account | 869,507 | 898,337 | 928,772 | 950,774 | 956,358 |
| Departmental expenses |  |   |  |  |  |
| Departmental appropriation (b) | 49,976 | 51,484 | 51,505 | 51,720 | 51,928 |
| Expenses not requiring appropriation in the Budget year (c) | 7,282 | 8,090 | 7,386 | 7,254 | 7,001 |
| Operating deficit (surplus) | - | - | - | - | - |
| **Total for Program 1.1** | **941,959** | **973,008** | **1,000,520** | **1,022,808** | **1,028,494** |
| **Total expenses for Outcome 1** | **941,959** | **973,008** | **1,000,520** | **1,022,808** | **1,028,494** |
|  |  |  |  |  |  |
|   | **2021–22** | **2022–23** |  |  |  |
| **Average staffing level (number)** | 183 | 178 |  |  |  |

(a) *Appropriation Act (No. 1) 2022–23.*

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1) and 'Revenue from independent sources (s74)'.

(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

#### Planned Performance for NHMRC

Table 2.1.2 details the performance measures for the program associated with Outcome 1. It also provides the related key activities as expressed in the current Corporate Plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, details of 2022–23 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance Measures for NHMRC

|  |
| --- |
| Outcome 1 |
| Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health. |
| Program Objective – Program 1.1: Health and Medical Research |
| The Australian Government, through NHMRC, aims to:* create knowledge and build research capability through investment in the highest quality health and medical research, and the best researchers (Investment)
* drive the translation of health and medical research into clinical practice, policy and health systems, and support the commercialisation of research discoveries (Translation)
* maintain a strong integrity framework underpinning rigorous and ethical research, and promoting community trust (Integrity).
 |
| Key Activities |
| * Investment:
* fund the best researchers and research across the breadth of Australian health and medical research needs, and invest in innovative and collaborative research projects
* fund research to improve health outcomes for Aboriginal and Torres Strait Islander people, and build and strengthen Aboriginal and Torres Strait Islander health researcher capacity.
* Translation:
* drive translation of evidence into innovative and evidence-based health care and public health policy, including by recognising Translation Centres
* develop and revise guidelines in public and environmental health and clinical practice to support consistent standards.

Integrity:* promote the highest standards of research quality and integrity, including leading the development and revision of key statements, codes and human research and ethics guidelines
* administer the *Research Involving Human Embryos Act 2002* and the *Prohibition of Human Cloning for Reproduction Act 2002* through the work of the Embryo Research Licensing Committee.
 |
| Performance Measures |
| Research grants in basic science, clinical medicine, public health and health services research meet the health needs of Australians, and include national, state and territory and community priorities. |
| Current Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results  | Forward Estimates2023–26 Planned Performance Results |
| Grants were awarded based on expert peer review across the full spectrum of health and medical research areas, and focused on achieving better health outcomes.[[2]](#footnote-2)More than 5% of NHMRC’s annual budget was expended/awarded on research that will provide better health outcomes for Aboriginal and Torres Strait Islander people.[[3]](#footnote-3) | Grants are awarded based on expert peer review across the full spectrum of health and medical research areas, and focus on achieving better health outcomes.[[4]](#footnote-4)More than 5% of NHMRC’s annual budget is expended/awarded on research that will provide better health outcomes for Aboriginal and Torres Strait Islander people. | As per 2022–23. |
| Support an Australian health system that is research-led, evidence-based, efficient and sustainable. |
| Current Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results  | Forward Estimates2023–26 Planned Performance Results |
| Improvements in clinical care, health service delivery and clinical training achieved by Translation Centres were identified and promoted.[[5]](#footnote-5)Public and environmental health and clinical practice guidelines continue to be developed and/or updated.[[6]](#footnote-6)  | Improvements in clinical care, health service delivery and clinical training achieved by Translation Centres are identified and promoted.[[7]](#footnote-7)Develop and/or approve public and environmental health and clinical practice guidelines. | As per 2022–23. |

|  |
| --- |
| **Promote and monitor the revised *Australian Code for the Responsible Conduct of Research* (the Code)and supporting guides.** |
| Current Year2021–22 Expected Performance Results | Budget Year2022–23 Planned Performance Results  | Forward Estimates2023–26 Planned Performance Results |
| Research integrity matters were managed appropriately by administering institutions in line with the requirements of the Code.[[8]](#footnote-8) | Research integrity matters are managed appropriately by administering institutions in line with the requirements of the Code. | As per 2022–23. |
| Material changes to Program 1.1 resulting from the following measures:There are no material changes to Program 1.1 resulting from measures. |

## Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2022–23 Budget year, including the impact of Budget measures and resourcing on financial statements.

### 3.1 Budgeted Financial Statements

#### 3.1.1 Differences between Entity Resourcing and Financial Statements

This section is not applicable to NHMRC.

#### 3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

#### Departmental Resources

**Comprehensive Income Statement (showing net cost of services)**

Revenue and expenditure for 2022–23 is expected to be in line with Government forecasts, with employee expenses to be 45% of total expenditure.

**Balance Sheet**

Assets and Liabilities are expected to remain stable across the Budget and forward years.

**Administered Resources**

The Administered accounts are used as a mechanism to transfer the majority of funds to NHMRC’s Special Account (Medical Research Endowment Account). In 2022–23, the transfer to the Special Account is expected to be $878 million.

### 3.2 Budgeted Financial Statements Tables

Table 3.1: Comprehensive Income Statement (showing net cost of services) for the period ended 30 June

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **EXPENSES** |  |   |  |  |  |
| Employee benefits | 26,133 | 26,656 | 27,189 | 27,736 | 28,298 |
| Supplier expenses | 23,749 | 24,761 | 24,275 | 23,971 | 23,646 |
| Depreciation and amortisation | 7,174 | 7,982 | 7,278 | 7,146 | 6,893 |
| Interest on RoU | 202 | 175 | 149 | 121 | 92 |
| **Total expenses** | **57,258** | **59,574** | **58,891** | **58,974** | **58,929** |
| **LESS:**  |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Sale of goods and rendering of services | 15,451 | 16,749 | 16,668 | 16,709 | 16,709 |
| **Total revenue** | **15,451** | **16,749** | **16,668** | **16,709** | **16,709** |
| **Gains** |  |  |  |  |  |
| Other | 108 | 108 | 108 | 108 | 108 |
| **Total gains** | **108** | **108** | **108** | **108** | **108** |
| **Total own-source income** | **15,559** | **16,857** | **16,776** | **16,817** | **16,817** |
| **Net cost of (contribution by) services** | **41,699** | **42,717** | **42,115** | **42,157** | **42,112** |
| Revenue from Government | 36,877 | 37,200 | 37,418 | 37,711 | 37,969 |
| **Surplus (deficit)** | **(4,822)** | **(5,517)** | **(4,697)** | **(4,446)** | **(4,143)** |
| **Surplus (deficit) attributable to the Australian Government** | **(4,822)** | **(5,517)** | **(4,697)** | **(4,446)** | **(4,143)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income (loss)** | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(4,822)** | **(5,517)** | **(4,697)** | **(4,446)** | **(4,143)** |
| **Note: Reconciliation of comprehensive income attributable to the agency** |   |
|  | **2021–22**$'000 | **2022–23** $'000 | **2023–24**$'000 | **2024–25**$'000 | **2025–26**$'000 |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(4,822)** | **(5,517)** | **(4,697)** | **(4,446)** | **(4,143)** |
| plus non-appropriated expenses depreciation and amortisation expenses | 4,600 | 5,142 | 4,606 | 4,481 | 4,286 |
| plus depreciation and amortisation expenses for RoU | 2,574 | 2,840 | 2,672 | 2,665 | 2,607 |
| less lease principal repayments | (2,352) | (2,465) | (2,581) | (2,700) | (2,750) |
| **Total comprehensive income (loss) attributable to the agency** | **-** | **-** | **-** | **-** | **-** |

RoU = Right-of-Use asset

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **ASSETS** |   |   |   |   |   |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 741  | 741  | 741  | 741  | 741  |
| Receivables | 4,715  | 4,715  | 4,715  | 4,715  | 4,715  |
| **Total financial assets** | **5,456**  | **5,456**  | **5,456**  | **5,456**  | **5,456**  |
| **Non-financial assets** |  |   |  |  |  |
| Property, plant and equipment | 3,251  | 2,410  | 2,089  | 1,900  | 1,727  |
| Land and buildings | 15,776  | 13,127  | 10,471  | 7,806  | 5,199  |
| Inventories | 89  | 89  | 89  | 89  | 89  |
| Intangibles | 23,410  | 19,097  | 14,977  | 10,866  | 6,934  |
| Other | 3,077  | 3,077  | 3,077  | 3,077  | 3,077  |
| **Total non-financial assets** | **45,603**  | **37,800**  | **30,703**  | **23,738**  | **17,026**  |
| **Total assets** | **51,059**  | **43,256**  | **36,159**  | **29,194**  | **22,482**  |
| **LIABILITIES** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 2,638  | 2,638  | 2,638  | 2,638  | 2,638  |
| Other payables | 4,290  | 4,290  | 4,290  | 4,290  | 4,290  |
| **Total payables** | **6,928**  | **6,928**  | **6,928**  | **6,928**  | **6,928**  |
| **Interest bearing liabilities** |  |   |  |  |  |
| Leases | 17,063 | 14,598  | 12,017 | 9,317 | 6,567 |
| **Total interest bearing liabilities** | **17,063** | **14,598**  | **12,017** | **9,317** | **6,567** |
| **Provisions** |  |   |  |  |  |
| Employees | 7,890  | 7,890  | 7,890  | 7,890  | 7,890  |
| **Total provisions** | **7,890**  | **7,890**  | **7,890**  | **7,890**  | **7,890**  |
| **Total liabilities** | **31,881**  | **29,416**  | **26,835**  | **24,135**  | **21,385**  |
| **Net Assets** | **19,178**  | **13,840**  | **9,324**  | **5,059**  | **1,097**  |
| **EQUITY** |  |   |  |  |  |
| Contributed equity | 17,022  | 17,201  | 17,382  | 17,563  | 17,744  |
| Reserves | 1,367  | 1,367  | 1,367  | 1,367  | 1,367  |
| Retained surpluses or (accumulated deficits) | 789  | (4,728) | (9,425) | (13,871) | (18,014) |
| **Total equity** | **19,178**  | **13,840**  | **9,324**  | **5,059**  | **1,097**  |

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | **Retained earnings** $'000 | **Asset revaluation reserve** $'000 | **Contributed equity/capital** $'000 | **Total equity** $'000 |
| **Opening balance as at 1 July 2022** |  |  |  |  |
| Balance carried forward from previous period | 789 | 1,367 | 17,022 | **19,178** |
| Surplus (deficit) for the period | (5,517) | - | - | **(5,517)** |
| Capital budget - Bill 1 (DCB) | - | - | 179 | **179** |
| **Estimated closing balance as at 30 June 2023** | **(4,728)** | **1,367** | **17,201** | **13,840** |

DCB = Departmental Capital Budget

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| Goods and services | 15,451 | 16,749 | 16,668 | 16,709 | 16,709 |
| Appropriations | 39,377 | 37,200 | 37,418 | 37,711 | 37,969 |
| **Total cash received** | **54,828** | **53,949** | **54,086** | **54,420** | **54,678** |
| **Cash used** |  |   |  |  |  |
| Employees | 26,133 | 26,656 | 27,189 | 27,736 | 28,298 |
| Suppliers | 23,641 | 24,653 | 24,167 | 23,863 | 23,538 |
| Interest payments on lease liability | 202 | 175 | 149 | 121 | 92 |
| **Total cash used** | **49,976** | **51,484** | **51,505** | **51,720** | **51,928** |
| **Net cash from (or used by) operating activities** | **4,852** | **2,465** | **2,581** | **2,700** | **2,750** |
| **INVESTING ACTIVITIES** |  |   |  |  |  |
| **Cash used** |  |   |  |  |  |
| Purchase of property, plant and equipment | 2,677 | 179 | 181 | 181 | 181 |
| **Total cash used** | **2,677** | **179** | **181** | **181** | **181** |
| **Net cash from (or used by) investing activities** | **(2,677)** | **(179)** | **(181)** | **(181)** | **(181)** |
| **FINANCING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Equity injections - Bill 2 | - | - | - | - | - |
| Capital budget - Bill 1 (DCB) | 177 | 179 | 181 | 181 | 181 |
| **Total cash received** | **177** | **179** | **181** | **181** | **181** |
| **Cash used** |  |   |  |  |  |
| Lease principal repayments | 2,352 | 2,465 | 2,581 | 2,700 | 2,750 |
| **Total cash used** | **2,352** | **2,465** | **2,581** | **2,700** | **2,750** |
| **Net cash from (or used by) financing activities** | **(2,175)** | **(2,286)** | **(2,400)** | **(2,519)** | **(2,569)** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 741 | 741 | 741 | 741 | 741 |
| **Cash and cash equivalents at the end of the reporting period** | **741** | **741** | **741** | **741** | **741** |

DCB = Departmental Capital Budget

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **CAPITAL APPROPRIATIONS** |   |  |  |   |   |
| Capital budget - Bill 1 (DCB) | 177 | 179 | 181 | 181 | 181 |
| Equity injections - Bill 2 | - | - | - | - | - |
| **Total capital appropriations** | **177** | **179** | **181** | **181** | **181** |
| **Total new capital appropriations represented by:** |   |  |  |   |   |
| Purchase of non-financial assets | 177 | 179 | 181 | 181 | 181 |
| **Total items** | **177** | **179** | **181** | **181** | **181** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |   |  |  |   |   |
| Funded by capital appropriations - equity injection (a) | -  | -  | -  | -  | -  |
| Funded by capital appropriation - DCB (b) | 177 | 179 | 181 | 181 | 181 |
| Funded internally from departmental resources | 2,500 | - | - | - | - |
| **Total acquisitions of non-financial assets** | **2,677** | **179** | **181** | **181** | **181** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |   |  |  |  |
| Total purchases | 2,677 | 179 | 181 | 181 | 181 |
| **Total cash used to acquire assets** | **2,677** | **179** | **181** | **181** | **181** |

DCB = Departmental Capital Budget

(a) Includes both current Bill 2 and prior Act 2, 4, 6 appropriations.

(b) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of Departmental Asset Movements (Budget year
2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings** $'000 | **Property, plant and equipment** $'000 | **Intangibles** $'000 | **Total** $'000 |
| **As at 1 July 2022** |  |  |  |  |
| Gross book value  | - | 4,726 | 41,517 | **46,243** |
| Gross book value - RoU | 23,437 | 767 | - | **24,204** |
| Accumulated depreciation/amortisation and impairment | - | (1,705) | (18,107) | **(19,812)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (7,661) | (537) | - | **(8,198)** |
| **Opening net book balance** | **15,776** | **3,251** | **23,410** | **42,437** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| By purchase - appropriation ordinary annual services | - | 179 | - | **179** |
| By purchase - RoU | - | - | - | **-** |
| **Total additions** | **-** | **179** | **-** | **179** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | - | (829) | (4,313) | **(5,142)** |
| Depreciation/amortisation expense - RoU | (2,649) | (191) | - | **(2,840)** |
| Other movements | - | - | - | **-** |
| **Total other movements** | **(2,649)** | **(1,020)** | **(4,313)** | **(7,982)** |
| **As at 30 June 2023** |  |  |  |  |
| Gross book value | - | 4,905 | 41,517 | **46,422** |
| Gross book value - RoU | 23,437 | 767 | - | **24,204** |
| Accumulated depreciation/ amortisation and impairment | - | (2,534) | (22,420) | **(24,954)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (10,310) | (728) | - | **(11,038)** |
| **Closing net book balance** | **13,127** | **2,410** | **19,097** | **34,634** |

RoU = Right-of-Use Asset

**Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| Grants - MREA | 869,507 | 898,337 | 928,772 | 950,774 | 956,358 |
| Suppliers | 15,194 | 15,097 | 12,857 | 13,060 | 13,207 |
| **Total expenses administered on behalf of Government** | **884,701** | **913,434** | **941,629** | **963,834** | **969,565** |
| **REVENUES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |  |  |  |  |
| Recoveries | 5,000 | 10,000 | 10,000 | 10,000 | 10,000 |
| **Total income administered on behalf of Government** | **5,000** | **10,000** | **10,000** | **10,000** | **10,000** |

MREA = Medical Research Endowment Account

**Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT** |   |   |   |   |   |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 215,698 | 205,313 | 177,635 | 142,216 | 114,843 |
| Receivables | 3,113 | 3,113 | 3,113 | 3,113 | 3,113 |
| **Total financial assets** | **218,811** | **208,426** | **180,748** | **145,329** | **117,956** |
| **Total assets administered on behalf of Government** | **218,811** | **208,426** | **180,748** | **145,329** | **117,956** |
| **LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Grants | 4,493 | 4,493 | 4,493 | 4,493 | 4,493 |
| Suppliers | 11,840 | 11,840 | 11,840 | 11,840 | 11,840 |
| Other | 213 | 213 | 213 | 213 | 213 |
| **Total payables** | **16,546** | **16,546** | **16,546** | **16,546** | **16,546** |
| **Total liabilities administered on behalf of Government** | **16,546** | **16,546** | **16,546** | **16,546** | **16,546** |

**Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| Cash received - other | 5,000 | 10,000 | 10,000 | 10,000 | 10,000 |
| Net GST received | 26,000 | 26,000 | 26,000 | 26,000 | 26,000 |
| **Total cash received** | **31,000** | **36,000** | **36,000** | **36,000** | **36,000** |
| **Cash used** |  |   |  |  |  |
| Grant payments  | 869,507 | 898,337 | 928,772 | 950,774 | 956,358 |
| Suppliers | 15,194 | 15,097 | 12,857 | 13,060 | 13,207 |
| Net GST paid | 26,000 | 26,000 | 26,000 | 26,000 | 26,000 |
| **Total cash used** | **910,701** | **939,434** | **967,629** | **989,834** | **995,565** |
| **Net cash from (or used by) operating activities** | **(879,701)** | **(903,434)** | **(931,629)** | **(953,834)** | **(959,565)** |
| **Net increase (or decrease) in cash held** | **(879,701)** | **(903,434)** | **(931,629)** | **(953,834)** | **(959,565)** |
| Cash at beginning of reporting period | 216,939 | 215,698 | 205,313 | 177,635 | 142,216 |
| Cash from the OPA for: |  |   |  |  |  |
| - appropriations | 878,460 | 893,049 | 903,951 | 918,415 | 932,192 |
| **Cash at end of reporting period** | **215,698** | **205,313** | **177,635** | **142,216** | **114,843** |

1. For more information about the strategic direction of NHMRC, refer to the current Corporate Plan, available at: www.nhmrc.gov.au/about-us/publications/nhmrc-corporate-plan-2021-22 [↑](#footnote-ref-1)
2. Details of grants awarded, including summaries by broad research area, are available at: www.nhmrc.gov.au/funding/data-research/outcomes-funding-rounds [↑](#footnote-ref-2)
3. The total expenditure as at 30 June 2022 will be reported in NHMRC’s 2021–22 Annual Report. [↑](#footnote-ref-3)
4. This target assesses the distribution of NHMRC grant expenditure and of new grants awarded. [↑](#footnote-ref-4)
5. Activities are detailed on NHMRC’s website, available at:
www.nhmrc.gov.au/about-us/resources/what-are-translation-centres-doing-and-why [↑](#footnote-ref-5)
6. Guidelines developed and updated by NHMRC will be reported in NHMRC’s 2021–22 Annual Report. [↑](#footnote-ref-6)
7. This target assesses the outcomes from NHMRC-accredited centres as evidence that the accreditation process is effective in supporting improvements in these areas. [↑](#footnote-ref-7)
8. Reporting on implementation of the Code is being collected in the Institutional Annual Compliance Report and will be reported in NHMRC’s 2021–22 Annual Report. [↑](#footnote-ref-8)